The foundation of successful ADCs is the targeting of cancer cells. Oxford BioTherapeutics’ OGAP® technology is a world leader in its field, and is specifically designed to define the best targets for the development of ADCs.
Targeting Cancer with Antibody-Drug Conjugates
Oxford BioTherapeutics is a leading company in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. These new therapies are designed to precisely deliver potent cancer-killing toxins directly to cancer cells. This is achieved by linking (conjugating) the chemotherapy agents to monoclonal antibodies, which are purpose-designed to target cancer cells and deliver their toxin load. By targeting proteins that are highly expressed on cancer cells, rather than healthy cells, this ADC ‘armed’ antibody approach offers the potential of greater efficacy while sparing normal tissue.
Combining Novel Technologies
A number of complementary technologies come together to empower the ADC approach.
Monoclonal antibodies bind to specific antigens, and have proved successful in targeting a number of cancers. Antibody development technologies are now well established and Oxford BioTherapeutics works with several leading companies to design its ADC antibodies.
Effective ADCs require linker compounds that are stable in blood and release their chemotherapy load once inside the target cancer cells. As the toxins are delivered at the cellular level they must be highly potent. Oxford BioTherapeutics works with a number of world-leading antibody arming companies to develop its ADCs.
Progressing novel treatments through development requires highly specialized capabilities and infrastructure. Oxford BioTherapeutics has established an innovative $1 billion development collaboration to access these skills, reflecting the significant potential of our ADCs.
Transforming Cancer Therapy
For many years cancer treatments have used monoclonal antibodies to target cancer cells, often in combination with traditional chemotherapy. However, many antibodies are not sufficiently effective to act as therapies alone. By combining the power of potent cancer toxins with the targeting abilities of antibodies, ADCs offer a new and revolutionary approach.
Following years of research, and the approval of Seattle Genetics’ ADCETRIS® (brentuximab vedotin) and Roche’s KADCYLA® (trastuzumab emtansine), this ADC approach is now becoming a reality.